Article Versions Notes

Boix L, Sapena V, Samper E, Díaz-González Á, Llarch N, Iserte G, Da Fonseca LG, Sanduzzi-Zamparelli M, Forner A, Bruix J, et al. Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. Gastrointestinal Disorders. 2022; 4(3):141-152. https://doi.org/10.3390/gidisord4030014

Boix, Loreto, Víctor Sapena, Esther Samper, Álvaro Díaz-González, Neus Llarch, Gemma Iserte, Leonardo G. Da Fonseca, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Bruix, and et al. 2022. "Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment" Gastrointestinal Disorders 4, no. 3: 141-152. https://doi.org/10.3390/gidisord4030014

Boix, L., Sapena, V., Samper, E., Díaz-González, Á., Llarch, N., Iserte, G., Da Fonseca, L. G., Sanduzzi-Zamparelli, M., Forner, A., Bruix, J., & Reig, M. (2022). Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. Gastrointestinal Disorders, 4(3), 141-152. https://doi.org/10.3390/gidisord4030014